At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed brain stem glioma (except if medically contraindicated) that is unlikely to respond to existing therapy
- ✓Tumor at least 5 mm in maximum diameter
- ✓Age 6 months or older
- ✓Karnofsky performance status 60-100%
- ✕Pregnant or nursing
- ✕Severe heart disease or uncontrolled hypertension
- ✕History of congestive heart failure
- ✕Cardiovascular conditions that contraindicate high dosages of sodium
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Brain Stem Glioma
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Brain Stem Gliomas. Completed, enrolled 40 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for a brain stem glioma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain stem gliomas. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children (\> 6 months of age) and adults with newly-diagnosed or recurrent brain stem gliomas.
Study Details
Timeline
Interventions
Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)